"description","bcCategories","label","studyInvestigationalInterventions","studyEstimands","name","studyDesignRationale","documentVersion","uuid:ID","id"
"The main design for the study","[]","","[]","[]","Study Design 1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","","05391022-4f40-4f17-a5bc-d939a46366ce","StudyDesign_1"
